REPEAT: Alaska Permanent Fund Takes Stake in Denali Therapeutics
Posted on 05/14/2015
Institutional investors are plunging billions into emerging, pre-IPO biotechnology companies. San Francisco-based Denali Therapeutics, a new biotechnology company that is focused on developing effective therapies for neurodegenerative diseases, such as Alzheimer’s, ALS, and Parkinson’s, raised a Series A round of US$ 217 million from investors. Some of the founders of Denali Therapeutics are former Genentech […]
- Alaska Permanent Fund Corporation
- Alternatives
- ARCH Ventures
- Biotech
- Genentech
- pharmaceuticals
- Venture Capital
